Tags : Truxima

Celltrion Report Results of Truxima (biosimilar, rituximab) Based Regimen in

Shots: Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m2) + lenalidomide (20mg, day 1-21, qd) + acalabrutinib (100mg, day 1-28, bid) (R2A) is well-tolerated and effective in relapsed/refractory aggressive B-cell lymphoma In the 13 patients who underwent disease assessment following the R2A regimen, ORR (69%) and CR (31%), […]Read More

Teva and Celltrion Reports the Availability of Truxima (biosimilar, Rituxan)

Shots: Teva and Celltrion launch Truxima (rituximab-abbs) injection as the first biosimilar referencing Roche’s Rituxan (rituximab) to be available in the US by the week of November 11, addressing the unmet medical needs of the patients in the US The approval of Truxima is based on clinical/ nonclinical, pharmacology, immunogenicity, clinical efficacy and safety data. […]Read More

Celltrion’s Truxima (rituximab-abbs) Receives FDA’s Approval for Three on-Hodgkin’s Lymphoma

Shots: The approval is based on non-inferiority data demonstrating biosimilarity in pharmacology, immunogenicity, clinical efficacy with safety, potency and purity when compared to reference medicine (rituxan) Truxima is a mAb, indicated and approved in three indications i.e. r/r, low-grade or follicular, CD20-positive, B-cell NHL, 1L patients with CD20-positive B-cell NHL and 1L Non-progressing low-grade CD20-positive […]Read More